Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1

Recruiting

Conditions: Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage III Lung Cancer

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Biological: Pembrolizumab
Drug: Nab-paclitaxel
Drug: Pemetrexed
Procedure: Positron Emission Tomography
Biological: Atezolizumab
Radiation: Radiation Therapy
Other: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Biological: Cemiplimab
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2022-08-15

Last Posted Date: 2024-10-17

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 25

Registration Number: NCT05501665

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Phase 1

Recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Drug: Ciforadenant

First Posted Date: 2022-08-15

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05501054

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Early Phase 1

Suspended

Conditions: Locally Advanced or Metastatic Melanoma

Interventions: Drug: CBL0137
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2022-08-12

Last Posted Date: 2024-03-20

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 12

Registration Number: NCT05498792

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Phase 2

Terminated

Conditions: Colonic Neoplasms
Colorectal Neoplasms

Interventions: Drug: GRT-C901
Drug: GRT-R902
Drug: Atezolizumab
Drug: Ipilimumab
Drug: Adjuvant chemotherapy

First Posted Date: 2022-07-13

Last Posted Date: 2022-11-25

Lead Sponsor: Gritstone bio, Inc.

Target Recruit Count: 1

Registration Number: NCT05456165

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Christ Hospital Cancer Center, Cincinnati, Ohio, United States
🇺🇸
NYU Langone Health, New York, New York, United States

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Phase 1

Active, not recruiting

Conditions: Myeloproliferative Neoplasms

Interventions: Biological: VAC85135
Drug: Ipilimumab

First Posted Date: 2022-07-06

Last Posted Date: 2024-10-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT05444530

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇬🇧
Churchill Hospital, Oxford, United Kingdom

and more 4 locations

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Phase 1

Recruiting

Conditions: Atypical Teratoid Rhabdoid Tumor
INI1 (SMARCB1)-deficient Primary CNS Malignant Tumors
SMARCA4-deficient Primary CNS Malignant Tumors
Malignant Rhabdoid Tumor (MRT)
Rhabdoid Tumor of the Kidney (RTK)
Epithelioid Sarcoma
Chordoma

Interventions: Drug: Tazemetostat
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2022-06-07

Last Posted Date: 2023-08-22

Lead Sponsor: Susan Chi, MD

Target Recruit Count: 49

Registration Number: NCT05407441

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986408
Biological: Nivolumab
Drug: Rabeprazole
Biological: Platinum-doublet chemotherapy
Biological: Ipilimumab

First Posted Date: 2022-06-07

Last Posted Date: 2024-11-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 101

Registration Number: NCT05407675

Locations: 🇺🇸
Local Institution - 0010, Boston, Massachusetts, United States
🇺🇸
Local Institution - 0001, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 0003, Houston, Texas, United States

and more 15 locations